SCAANT1: A Potential Drug Target and Biomarker (G100861563)

Target Name: SCAANT1

NCBI ID: G100861563

SCAANT1

Other Name(s): SCA7/ATXN7 antisense RNA 1 (non-protein coding) | SCA7/ATXN7 antisense RNA 1 | ATXN7-AS1 | Spinocerebellar ataxia-7 antisense noncoding transcript 1 | ATXN7 antisense RNA 1 (non-protein coding)

SCAANT1: A Potential Drug Target and Biomarker

SCAANT1 (secretory cell-associated antigen 1) is a protein that is expressed in various tissues and cells of the human body. It is a member of the secretory cell-associated antigen (SCA) family, which includes proteins that are involved in cell-mediated signaling and communication. SCAANT1 has been identified as a potential drug target and biomarker for various diseases, including cancer, neurodegenerative diseases, and autoimmune disorders.

The SCAANT1 protein is expressed in a variety of tissues and cells, including the brain, pancreas, and gastrointestinal tract. It is also expressed in various types of cancer, including lung, breast, and ovarian cancer. SCAANT1 has been shown to be involved in cell signaling and communication, which suggests that it may play a role in the development and progression of these diseases.

One of the key functions of SCAANT1 is its role in the production and release of insulin. Insulin is a hormone that is produced by the pancreas and helps to regulate blood sugar levels. SCAANT1 has been shown to be involved in the regulation of insulin secretion by the pancreas, and it has been suggested that alterations in SCAANT1 levels or activity may contribute to the development of insulin-dependent diabetes.

In addition to its role in insulin production, SCAANT1 is also involved in the regulation of other physiological processes that are important for human health, including cell signaling and communication, inflammation, and stress response. SCAANT1 has been shown to be involved in a variety of signaling pathways that are important for these processes, including the TGF-β pathway, the PI3K/Akt pathway, and the NF-kappa-B pathway.

SCAANT1 has also been shown to be involved in the development and progression of certain types of cancer. For example, SCAANT1 has been shown to be involved in the development of neurofibromatosis, a genetic disorder that is characterized by the formation of tumors on nerves. SCAANT1 has also been shown to be involved in the development of cancer by promoting the growth and survival of cancer cells.

In addition to its potential role as a drug target and biomarker, SCAANT1 is also of interest as a potential therapeutic target for a variety of diseases. For example, SCAANT1 has been shown to be involved in the regulation of insulin secretion, which suggests that it may be a useful target for interventions that target insulin production or sensitivity. In addition, SCAANT1 is involved in the regulation of cell signaling and communication, which suggests that it may be a useful target for interventions that target inflammation or stress response.

Overall, SCAANT1 is a protein that is expressed in a variety of tissues and cells and is involved in a variety of physiological processes that are important for human health. Its potential as a drug target and biomarker for various diseases makes it an attractive target for further research and development.

Protein Name: SCA7/ATXN7 Antisense RNA 1

The "SCAANT1 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about SCAANT1 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets